Alto Neuroscience (NYSE:ANRO) Sees Large Volume Increase – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares saw unusually-high trading volume on Monday . Approximately 308,826 shares changed hands during trading, a decline of 10% from the previous session’s volume of 341,491 shares.The stock last traded at $25.8730 and had previously closed at $26.48.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ANRO. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Wolfe Research started coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. JonesTrading lowered their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Chardan Capital restated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, Wedbush boosted their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Trading Down 0.8%

The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The business has a 50-day simple moving average of $22.97 and a two-hundred day simple moving average of $21.02. The stock has a market cap of $975.43 million, a price-to-earnings ratio of -11.49 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, research analysts forecast that Alto Neuroscience, Inc. will post -2.97 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ANRO. AQR Capital Management LLC bought a new stake in Alto Neuroscience during the 1st quarter worth about $52,000. Torren Management LLC acquired a new position in shares of Alto Neuroscience during the 4th quarter worth about $62,000. Invesco Ltd. acquired a new position in shares of Alto Neuroscience during the 1st quarter worth about $67,000. Bridgeway Capital Management LLC grew its holdings in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $198,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.